SAN DIEGO and VANCOUVER, British Columbia, Nov. 10, 2015 /PRNewswire/ — Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced final results from its Phase 3 “PLUS-1” study of PRX302 as a treatment for lower urinary tract symptoms …